Cargando…

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study

BACKGROUND: Nocturnal hypertension is an important phenotype of abnormal diurnal blood pressure (BP) variability and a known risk marker for target organ damage and cardiovascular events. This study aimed to assess the differential BP-lowering effects of esaxerenone vs. eplerenone on nocturnal BP in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kario, Kazuomi, Ito, Sadayoshi, Itoh, Hiroshi, Rakugi, Hiromi, Okuda, Yasuyuki, Yoshimura, Motonobu, Yamakawa, Satoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140658/ https://www.ncbi.nlm.nih.gov/pubmed/33165570 http://dx.doi.org/10.1093/ajh/hpaa155

Ejemplares similares

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
por: Kario, Kazuomi, et al.
Publicado: (2021)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial
por: Okuda, Yasuyuki, et al.
Publicado: (2022)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
por: Rahman, Asadur, et al.
Publicado: (2021)

Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
por: Chang, Wei-Ting, et al.
Publicado: (2021)

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
por: Tezuka, Yuta, et al.
Publicado: (2022)

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2019)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020)

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
por: Ito, Sadayoshi, et al.
Publicado: (2019)

Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker
por: Arai, Kiyoshi, et al.
Publicado: (2020)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
por: Itoh, Hiroshi, et al.
Publicado: (2019)

Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study
por: Kario, Kazuomi, et al.
Publicado: (2023)

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
por: Munkhjargal, Uugantsetseg, et al.
Publicado: (2023)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies
por: Ito, Sadayoshi, et al.
Publicado: (2023)

Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
por: Kario, Kazuomi, et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Sleep and nocturnal hypertension: Genes, environment, and individual profiles
por: Kario, Kazuomi
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial
por: Weber, Michael A., et al.
Publicado: (2022)

SUN-176 A Case of Aldosterone-Producing Adenoma with Preoperative Use of a Novel Mineralocorticoid Receptor Antagonist Esaxerenone
por: Yamanami, Hiroaki
Publicado: (2020)

Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone
por: Qiang, Panpan, et al.
Publicado: (2022)

Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE‐HT study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
por: Ito, Sadayoshi, et al.
Publicado: (2021)

Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonists and Protection Against Cardiovascular Disease in Patients with Diabetes Mellitus
por: Shimabukuro, Michio
Publicado: (2023)

Comparison of nighttime measurement schedules using a wrist‐type nocturnal home blood pressure monitoring device
por: Tomitani, Naoko, et al.
Publicado: (2021)

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies
por: Shikata, Kenichi, et al.
Publicado: (2022)

Nocturnal blood pressure surge in seconds is associated with arterial stiffness independently of conventional nocturnal blood pressure variability in suspected obstructive sleep apnea patients
por: Kokubo, Ayako, et al.
Publicado: (2023)

Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial
por: Kario, Kazuomi, et al.
Publicado: (2022)

Reproducibility of nighttime home blood pressure measured by a wrist‐type nocturnal home blood pressure monitoring device
por: Tomitani, Naoko, et al.
Publicado: (2021)

Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry
por: Mahfoud, Felix, et al.
Publicado: (2017)

Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation
por: Kario, Kazuomi, et al.
Publicado: (2023)

Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure
por: Fujiwara, Takeshi, et al.
Publicado: (2021)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6rop8omhcr7s379eei0hb08ssi